Literature DB >> 18628094

High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer.

Lisa Simi1, Nicola Pratesi, Marina Vignoli, Roberta Sestini, Fabio Cianchi, Rosa Valanzano, Stefania Nobili, Enrico Mini, Mario Pazzagli, Claudio Orlando.   

Abstract

High-resolution melting analysis (HRMA) provides a valid approach to efficiently detect DNA genetic and somatic mutations. In this study, HRMA was used for the screening of 116 colorectal cancers (CRCs) to detect hot-spot mutations in the KRAS and BRAF oncogenes. Mutational hot spots on the PIK3CA gene, exons 9 and 20, were also screened. Direct sequencing was used to confirm and characterize HRMA results. HRMA revealed abnormal melting profiles in 65 CRCs (56.0%), 16 of them harboring mutations in 2 different genes simultaneously. The frequency of mutations was 17.2% for PIK3CA (11.2% in exon 9 and 6.0% in exon 20), 43.1% for KRAS exon 2, and 9.5% in exon 15 of the BRAF gene. We found a significant association between PIK3CA and KRAS mutations (P = .008), whereas KRAS and BRAF mutations were mutually exclusive (P = .001). This report describes a novel approach for the detection of PIK3CA somatic mutations by HRMA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18628094     DOI: 10.1309/LWDY1AXHXUULNVHQ

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  79 in total

Review 1.  High-throughput screening strategies for targeted identification of therapeutic compounds in colorectal cancer.

Authors:  Agnieszka B Bialkowska; Vincent W Yang
Journal:  Future Oncol       Date:  2012-03       Impact factor: 3.404

2.  ERK and Akt signaling pathways function through parallel mechanisms to promote mTORC1 signaling.

Authors:  Jeremiah N Winter; Leonard S Jefferson; Scot R Kimball
Journal:  Am J Physiol Cell Physiol       Date:  2011-02-02       Impact factor: 4.249

3.  LightCycler technology in molecular diagnostics.

Authors:  Elaine Lyon; Carl T Wittwer
Journal:  J Mol Diagn       Date:  2009-02-05       Impact factor: 5.568

4.  Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.

Authors:  Monica Mita; Siqing Fu; Sarina Anne Piha-Paul; Filip Janku; Alain Mita; Ronald Natale; Wei Guo; Charles Zhao; Razelle Kurzrock; Aung Naing
Journal:  Invest New Drugs       Date:  2017-02-13       Impact factor: 3.850

Review 5.  Synchronous occurrence of medullary and papillary carcinoma of the thyroid in a patient with cutaneous melanoma: determination of BRAFV600E in peripheral blood and tissues. Report of a case and review of the literature.

Authors:  Benedetta Fibbi; Pamela Pinzani; Francesca Salvianti; Matteo Rossi; Luisa Petrone; Maria Laura De Feo; Roberto Panconesi; Vania Vezzosi; Simonetta Bianchi; Gabriele Simontacchi; Monica Mangoni; Maurizio Pertici; Gianni Forti; Cinzia Pupilli
Journal:  Endocr Pathol       Date:  2014-09       Impact factor: 3.943

6.  KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology.

Authors:  Wilko Weichert; Christiane Schewe; Annika Lehmann; Christine Sers; Carsten Denkert; Jan Budczies; Albrecht Stenzinger; Hans Joos; Olfert Landt; Volker Heiser; Christoph Röcken; Manfred Dietel
Journal:  J Mol Diagn       Date:  2009-12-10       Impact factor: 5.568

7.  New insights into 4E-BP1-regulated translation in cancer progression and metastasis.

Authors:  Jun Wang; Qing Ye; Qing-Bai She
Journal:  Cancer Cell Microenviron       Date:  2014

8.  COLD-HRM PCR versus conventional HRM PCR to detect the BRAF V600E mutation A real improvement?

Authors:  Elke Stadelmeyer; Ellen Heitzer; Peter Wolf; Nadia Dandachi
Journal:  J Mol Diagn       Date:  2011-03       Impact factor: 5.568

9.  MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1).

Authors:  Defang Sun; Feng Yu; Yutao Ma; Ran Zhao; Xi Chen; Jie Zhu; Chen-Yu Zhang; Jiangning Chen; Junfeng Zhang
Journal:  J Biol Chem       Date:  2013-01-15       Impact factor: 5.157

10.  KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer.

Authors:  Wilbur A Franklin; Jerry Haney; Michio Sugita; Lynne Bemis; Antonio Jimeno; Wells A Messersmith
Journal:  J Mol Diagn       Date:  2009-12-10       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.